The head of the Ministry of Health of Russia Mikhail Murashko announced the development of new methods of cancer treatment in the Russian Federation. According to him, they will be available to patients in 2023."Several technologies are already being worked out in 2021-2022, and in 2023 they will be available to patients," the minister said.

The editorial board of "Made in Russia" turned to the doctor, oncologist surgeon "SM-Clinic", candidate of Medical Sciences Dmitry Zinatulin.

According to him, intraperitoneal hyperthermic chemoperfusion (HIPEC) is currently being mastered in the Russian Federation, despite the fact that its use has long been in practice in many foreign clinics. Based on the existing experience, we can confidently say that intraperitoneal hyperthermochemotherapy provides patients with a chance that they did not have before.

"If earlier the survival rate of patients with multiple tumor metastasis to the peritoneum (peritoneal carcinomatosis) was about six months to a year, then thanks to the HIPEC technique, the average life expectancy of patients with primary peritoneal tumors is more than 7 years; with metastatic lesions of the peritoneum due to stomach cancer, the average life expectancy is 37 months, with metastases resulting from the development of ovarian cancer - 45 months," - said Zinatulin.Before the advent of the new technique, the treatment of some cancers associated with the development of peritoneal carcinomatosis was seriously complicated by the fact that the size of metastases did not always allow them to be surgically removed.

And it was extremely undesirable to leave these "grains" inside, since after a few months they "germinated" in other organs, and the cancer recurred. At the same time, since there are practically no blood vessels in the peritoneum, conventional chemotherapy (intravenous or oral) was often ineffective, because drugs, in fact, had very little effect on metastases.

You should know that HIPEC is not an independent procedure. This is a combined approach in which oncosurgeons first remove the tumor, after which, with the participation of a chemotherapist, the patient's abdominal cavity is washed with a heated solution of a chemotherapy drug. The device used for HIPEC controls the temperature of the chemotherapeutic drug injected into the abdominal cavity and its volume throughout the procedure. At the end of the procedure, oncosurgeons complete the surgical stage of the intervention.

The decision to perform the operation in combination with HIPEC is made on the basis of the conclusion of the oncological consultation, through which all oncological patients pass. In addition, specialists such as anesthesiologists, resuscitators, therapists and cardiologists evaluate individual risk factors - first of all, the patient's condition itself. To assess the degree of damage to the abdominal tumor process, a special scale is used – the index of peritoneal carcinomatosis. If a decision is made to perform an operation, the patient is hospitalized in a hospital.

After the operation, the patient stays in the hospital for up to two weeks while doctors monitor his recovery. After discharge, the patient is regularly monitored and examined by his attending physician. It is worth noting that HIPEC performing surgery together does not exclude subsequent courses of traditional chemotherapy prescribed to patients to help them finally cope with cancer. These courses are conducted as regularly as necessary.

Read more interesting news in our Telegram channelAuthor: Alexander Baigazin

Made in Russia // Made in Russia

#made by Russia